Epstein-Barr virus-associated gastric cancer: disease that requires special approach.
Ekaterina O IgnatovaDaria SeriakMikhail FedyaninAlexey TryakinIlya PokataevSofia MenshikovaYuliya VakhabovaKsenia SmirnovaSergey TjulandinJaffer A AjaniPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2020)
Epstein-Barr virus-associated gastric cancer [EBV-associated GC, EBV( +) GC] is a distinct molecular subtype of gastrointestinal (GI) cancers. It accounts for up to 10% of all molecular subtypes of gastric cancer (GC). It has unique genetic and epigenetic features, which determine its definitive phenotype with male and younger age predominance, proximal stomach localization, and diffuse adenocarcinoma histology. EBV( +) GC also has a unique epigenetic profile and mutational status with frequent mutations of PIK3CA, ARID1A and BCOR, and PD-L1 and PD-L2 amplifications, as well. The aim of this review is to highlight clinical significance of EBV( +) GC and prognostic role of EBV infection, and to determine potentially appropriate drug therapy for this disease.